The startup develops microbiome-modulating drugs that restore microbial diversity to prevent bacterial infections in patients with serious medical needs. Their tailored high-diversity therapeutics enhance the microbiome's resilience, enabling effective prevention and treatment of debilitating infections and diseases.
Funding
$105M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KLKVSESNSVTBFounders
Product
Problem
Patients with serious medical needs are susceptible to bacterial infections due to a lack of microbial diversity in their gut. Current treatments often fail to address the underlying imbalance in the gut microbiome, leading to recurring infections and debilitating diseases.
Solution
EnteroBiotix develops orally administered, full-spectrum microbiome therapeutics designed to restore and enhance gut microbial ecology, preventing and treating infections. Their Intestinal Microbial Transfer (IMT) therapies utilize microorganisms sourced from healthy donors, delivering a consistent, stable, and high-diversity anaerobic microbiota. The unique powder formulation allows for ambient temperature stability and is delivered via an oral capsule without the need for bowel preparation. By rebuilding the foundation of gut health, EnteroBiotix aims to address the balance and function of the microbiome, going beyond simply treating symptoms.
Target Audience
The primary target audience includes patients with impaired gut function and related conditions, as well as healthcare providers seeking innovative solutions for preventing and treating microbiome-related infections.
Features
- Full-spectrum microbial ecosystems sourced from exceptionally healthy donors with desirable characteristics
- Unique powder formulation delivering high-diversity anaerobic microbiota in a stable, easy-to-administer oral capsule
- Proprietary AMPLA™ drying technology for ambient temperature stability
- PRISM™: Sophisticated analytical toolkit for precise microbial characterization
- In-house donor program Number 2® ensures control over the supply chain
- State-of-the-art GMP manufacturing capabilities